The end of my belief came on a fall night in 2011. I was driving to a suburban restaurant to give a paid dinner talk on Niaspan for Abbott Labs. It was a typical night for a physician speaker—slide deck polished, HDL-cholesterol optimism intact. Then the results of the AIM-HIGH trial came over public radio.
Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.